Literature DB >> 25630876

Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension.

Mylène Vaillancourt1, Grégoire Ruffenach1, Jolyane Meloche2, Sébastien Bonnet3.   

Abstract

Pulmonary arterial hypertension (PAH) is characterized by remodelling of pulmonary arteries caused by a proliferation/apoptosis imbalance within the vascular wall. This pathological phenotype seems to be triggered by different environmental stress and injury events such as increased inflammation, DNA damage, and epigenetic deregulation. It appears that one of the first hit to occur is endothelial cells (ECs) injury and apoptosis, which leads to paracrine signalling to other ECs, pulmonary artery smooth muscle cells (PASMCs), and fibroblasts. These signals promote a phenotypic change of surviving ECs by disturbing different signalling pathways leading to sustained vasoconstriction, proproliferative and antiapoptotic phenotype, deregulated angiogenesis, and formation of plexiform lesions. EC signalling also recruits proinflammatory cells, leading to pulmonary infiltration of lymphocytes, macrophages, and dendritic cells, sustaining the inflammatory environment and autoimmune response. Finally, EC signalling promotes proliferative and antiapoptotic PAH-PASMC phenotypes, which acquire migratory capacities, resulting in increased vascular wall thickness and muscularization of small pulmonary arterioles. Adaptation and remodelling of pulmonary circulation also involves epigenetic components, such as microRNA deregulation, DNA methylation, and histone modification. This review will focus on the different cellular and epigenetic aspects including EC stress response, molecular mechanisms contributing to PAH-PASMC and PAEC proliferation and resistance to apoptosis, as well as epigenetic control involved in adaptation and remodelling of the pulmonary circulation in PAH.
Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25630876     DOI: 10.1016/j.cjca.2014.10.023

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  37 in total

1.  Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cell-Dependent Endothelial Cell Apoptosis.

Authors:  Grégoire Ruffenach; Ellen O'Connor; Mylène Vaillancourt; Jason Hong; Nancy Cao; Shervin Sarji; Shayan Moazeni; Jeremy Papesh; Victor Grijalva; Christine M Cunningham; Le Shu; Arnab Chattopadhyay; Shuchita Tiwari; Olaf Mercier; Frédéric Perros; Soban Umar; Xia Yang; Aldrin V Gomes; Alan M Fogelman; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Hypertension       Date:  2020-07-27       Impact factor: 10.190

2.  Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension.

Authors:  A Zimmer; R B Teixeira; J H P Bonetto; R Siqueira; C C Carraro; L M Donatti; A Hickmann; I E Litvin; A E G Godoy; A S Araujo; R Colombo; Adriane Belló-Klein
Journal:  Mol Cell Biochem       Date:  2017-02-08       Impact factor: 3.396

Review 3.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

4.  Transient Receptor Potential Channel 4 Encodes a Vascular Permeability Defect and High-Frequency Ca(2+) Transients in Severe Pulmonary Arterial Hypertension.

Authors:  Michael Francis; Ningyong Xu; Chun Zhou; Troy Stevens
Journal:  Am J Pathol       Date:  2016-04-12       Impact factor: 4.307

5.  Molecular mechanisms in vascular injury induced by hypertension: Expression and role of microRNA-34a.

Authors:  Siguan Liu; Fanfan Yi; Wenwei Cheng; Xin Qu; Chunting Wang
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

6.  Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension.

Authors:  Kang Wu; Haiyang Tang; Ruizhu Lin; Shane G Carr; Ziyi Wang; Aleksandra Babicheva; Ramon J Ayon; Pritesh P Jain; Mingmei Xiong; Marisela Rodriguez; Shamin Rahimi; Francesca Balistrieri; Shayan Rahimi; Daniela Valdez-Jasso; Tatum S Simonson; Ankit A Desai; Joe G N Garcia; John Y-J Shyy; Patricia A Thistlethwaite; Jian Wang; Ayako Makino; Jason X-J Yuan
Journal:  Pulm Circ       Date:  2020-09-10       Impact factor: 3.017

7.  Resistance Exercise Training Mitigates Left Ventricular Dysfunctions in Pulmonary Artery Hypertension Model.

Authors:  Leôncio Lopes Soares; Luciano Bernardes Leite; Luiz Otávio Guimarães Ervilha; Bruna Aparecida Fonseca da Silva; Maíra Oliveira de Freitas; Alexandre Martins Oliveira Portes; Leonardo Mateus Teixeira Rezende; Filipe Rios Drummond; Miguel Araújo Carneiro-Júnior; Mariana Machado Neves; Emily Correna Carlo Reis; Antônio José Natali
Journal:  Arq Bras Cardiol       Date:  2022-09-02       Impact factor: 2.667

8.  Loss of Amphiregulin drives inflammation and endothelial apoptosis in pulmonary hypertension.

Authors:  Jonathan Florentin; Jingsi Zhao; Yi-Yin Tai; Wei Sun; Lee L Ohayon; Scott P O'Neil; Anagha Arunkumar; Xinyi Zhang; Jianhui Zhu; Yassmin Al Aaraj; Annie Watson; John Sembrat; Mauricio Rojas; Stephen Y Chan; Partha Dutta
Journal:  Life Sci Alliance       Date:  2022-06-22

9.  NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis.

Authors:  Li-Huang Zha; Jun Zhou; Tang-Zhiming Li; Hui Luo; Jing-Ni He; Lin Zhao; Zai-Xin Yu
Journal:  Aging Dis       Date:  2018-10-01       Impact factor: 6.745

10.  Monocyte and Alveolar Macrophage Skewing Is Associated with the Development of Pulmonary Arterial Hypertension in a Primate Model of HIV Infection.

Authors:  Finja Schweitzer; Rebecca Tarantelli; Emily Rayens; Heather M Kling; Joshua T Mattila; Karen A Norris
Journal:  AIDS Res Hum Retroviruses       Date:  2018-10-30       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.